• Domingo J Palmero, Laura Lagrutta, Sandra J Inwentarz, Marisa Vescovo, Omar J Aidar, and Pablo J González Montaner.
• Hospital de Infecciosas Dr. Francisco Javier Muñiz, Buenos Aires, Argentina. E-mail: djpalmero@intramed.net.
• Medicina (B Aires). 2022 Jan 1; 82 (1): 117-129.

AbstractSince 2018, important changes in the treatment of drug-resistant tuberculosis have been produced in the light of new evidence. The discovery of new anti-tuberculosis drugs, such as bedaquiline and nitroimidazopirane derivatives, as well as the use of repurposed drugs, led to international organizations to recommend new, totally oral, treatment regimens for mono-resistant and multidrug-resistant tuberculosis, leaving aside the prolonged use of injectables, with their inherent toxicity and discomfort. Some definitions of drug-resistant tuberculosis have changed. The duration of treatment is also under review, leading some new regimens under study, such as BPaL (bedaquiline, pretomanid and linezolid), to a duration similar to that for treating susceptible tuberculosis. In this narrative review, we describe the new definitions, some basic diagnostic aspects, the pharmacological aspects, and the new classification of drugs to be used in the treatment of drug-resistant tuberculosis as well as the currently proposed schemes to treat it available within the Argentinean context. Finally, we include a brief review of ongoing clinical trials on new shortened treatments.

12 keywords...

hide…